28/04/2023 – AB Science reports its revenues for the year 2022 and provides an update on its activities Download PDF Post navigationPreviousPrevious post:Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual MeetingNextNext post:AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letterRelated PostsAB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development SummitMay 17, 2023AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letterMay 9, 2023Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual MeetingApril 27, 2023Presentation on masitinib in ALS delivered at 2023 AAN Annual MeetingApril 27, 2023Success of the capital increase by private placement for an amount of 15 million eurosApril 24, 2023Implementation of a new strategy and launch of a capital increaseApril 21, 2023
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development SummitMay 17, 2023
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letterMay 9, 2023
